Abstract

Pre-eclampsia is the most common pregnancy complication affecting 1 in 20 pregnancies, characterized by high blood pressure and signs of organ damage, most often to the liver and kidneys. Metabolic network analysis of published lipidomic data points to a shortage of Coenzyme A (CoA). Gene expression profile data reveal alterations to many areas of metabolism and, crucially, to conflicting cellular regulatory mechanisms arising from the overproduction of signalling lipids driven by CoA limitation. Adverse feedback loops appear, forming sphingosine-1-phosphate (a cause of hypertension, hypoxia and inflammation), cytotoxic isoketovaleric acid (inducing acidosis and organ damage) and a thrombogenic lysophosphatidyl serine. These also induce mitochondrial and oxidative stress, leading to untimely apoptosis, which is possibly the cause of CoA restriction. This work provides a molecular basis for the signs of pre-eclampsia, why polycystic ovary syndrome is a risk factor and what might be done to treat and reduce the risk of disease.

Highlights

  • Pre-eclampsia is a significant cause of maternal and foetal morbidity and mortality, accounting for at least 63,000 maternal deaths per annum [1]

  • This work has studied pre-eclampsia by examining data from molecular up to population scales. It points to a shortage of Coenzyme A (CoA) as a feature leading to the production of signalling lipids and toxic metabolites that induce vasoconstriction, inflammation, oxidative stress, thrombogenesis, acidosis, apoptosis and neurotoxicity

  • 14 were either signalling molecules or markers/agents of adverse physiological conditions found in pre-eclampsia, such as 2-hydroxybutanoate and oxo-methylbutanoic acid (Table 1)

Read more

Summary

Introduction

Pre-eclampsia is a significant cause of maternal and foetal morbidity and mortality, accounting for at least 63,000 maternal deaths per annum [1]. Proteomics data are less useful because disruption of the syncytiotrophoblast results in intracellular proteins masking any potential signalling molecules [3] This makes interpretation of biomarkers in common between PCOS and PE difficult to interpret [6]. This work has studied pre-eclampsia by examining data from molecular up to population scales It points to a shortage of Coenzyme A (CoA) as a feature leading to the production of signalling lipids and toxic metabolites that induce vasoconstriction, inflammation, oxidative stress, thrombogenesis, acidosis, apoptosis and neurotoxicity. It explains why PCOS is a risk factor for PE and points to potential treatments plus areas for further investigation

Metabolomic Data Indicate Restricted Coenzyme A Levels and Signalling Lipid Formation
Transcriptomic Data in
CoA Release and Changes to mRNA Levels Explain Elevated Signalling Lipids and Toxic Compounds
Multiple Conflicting Regulatory Pathways Arise from the Elevated Signalling Lipids
Population Variation
Systems Pathology in PE
PCOS and Other Risk Factors
Apoptosis and CoA
Potential Avenues for Translation, Prevention and Treatment
Data and Methods
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.